What are the best medications for treating Clostridioides difficile (C. diff) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Best Medications for Treating C. difficile Infection

For initial episodes of C. difficile infection (CDI), oral vancomycin (125 mg four times daily for 10 days) or fidaxomicin (200 mg twice daily for 10 days) are recommended as first-line treatments over metronidazole, with fidaxomicin being preferred due to lower recurrence rates. 1, 2

Initial Treatment Based on Disease Severity

Non-severe CDI:

  • Fidaxomicin 200 mg orally twice daily for 10 days (preferred first-line option) 2, 3
  • Vancomycin 125 mg orally four times daily for 10 days (alternative first-line option) 1, 4
  • Metronidazole 500 mg orally three times daily for 10 days can be considered in resource-limited settings, but has lower efficacy than vancomycin, particularly in severe cases 1

Severe CDI:

  • Vancomycin 125 mg orally four times daily for 10 days (recommended) 1
  • Fidaxomicin 200 mg orally twice daily for 10 days (alternative with lower recurrence rates) 1, 5
  • Higher vancomycin doses (500 mg four times daily) have not shown significant differences in cure rates compared to standard dosing 1, 6

Fulminant CDI or Complicated Infection:

  • Vancomycin 500 mg orally four times daily plus intravenous metronidazole 500 mg three times daily 1
  • For patients unable to take oral medications: intravenous metronidazole 500 mg three times daily plus vancomycin retention enema 500 mg in 100 mL normal saline four times daily 1, 2

Treatment for Recurrent CDI

First Recurrence:

  • Fidaxomicin 200 mg orally twice daily for 10 days (preferred option) 1, 7
  • Vancomycin as a tapered and pulsed regimen rather than a standard 10-day course 1, 8
  • If metronidazole was used for the initial episode, use vancomycin 125 mg four times daily for 10 days 1

Multiple Recurrences (≥2):

  • Vancomycin in a tapered and pulsed regimen (125 mg four times daily for 10-14 days, then twice daily for 7 days, then once daily for 7 days, then every 2-3 days for 2-8 weeks) 1
  • Vancomycin 125 mg four times daily for 10 days, followed by rifaximin 400 mg three times daily for 20 days 1, 8
  • Fidaxomicin 200 mg twice daily for 10 days 1
  • Fecal microbiota transplantation (FMT) is strongly recommended after at least 2 recurrences that have failed appropriate antibiotic treatments 1, 8, 9

Special Considerations

  • Discontinue the inciting antibiotic agent(s) as soon as possible to improve treatment outcomes 2
  • For patients who cannot take oral medications, intravenous metronidazole plus vancomycin retention enema is recommended 1, 2
  • Vancomycin enema dosing: 250-500 mg in 100-500 mL saline administered 2-4 times daily via rectal tube or catheter 2
  • Faecal levels of vancomycin are proportional to the dosage administered and remain much higher than the MIC90 against C. difficile even in patients with increased stool frequency 10
  • Avoid repeated metronidazole courses due to risk of cumulative and potentially irreversible neurotoxicity 2, 8

Treatment Efficacy Comparison

  • Fidaxomicin has shown similar clinical cure rates to vancomycin (88.2% vs. 85.8%) but significantly lower recurrence rates (15.4% vs. 25.3%) 5
  • For first recurrence, fidaxomicin demonstrated lower second recurrence rates compared to vancomycin (19.7% vs. 35.5%) 7
  • In severe CDI, vancomycin has demonstrated superior cure rates compared to metronidazole (97% vs. 76%) 1

Monitoring and Follow-up

  • Clinical response typically requires 3-5 days after starting therapy 2
  • "Test of cure" is not recommended after CDI treatment 2
  • Be vigilant for treatment failure, particularly in older patients with hypoalbuminemia 2
  • Approximately 20% of patients experience recurrence, with higher risk in elderly patients and those with continued antibiotic use 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Intravenous Alternative for Fidaxomicin in NPO Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Fidaxomicin versus vancomycin for Clostridium difficile infection.

The New England journal of medicine, 2011

Research

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012

Guideline

Second-Line Treatment for C. difficile Infection After Vancomycin Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of Severe and Fulminnant Clostridioides difficile Infection.

Current treatment options in gastroenterology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.